Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026)
Intellia Therapeutics (NTLA) reported FCF Margin of 780.34% for Q1 2026, up 11587.0% year-over-year from N/an in Q1 2025, and down 159.11% quarter-over-quarter from 301.16% in Q4 2025.
Intellia Therapeutics (NTLA) FCF Margin (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has 12 years of FCF Margin data on file, last reported at 780.34% in Q1 2026.
- FCF Margin for Q1 2026 came in at 780.34%, up 11587.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 549.51% (up 27408.0% YoY), and the FY2025 annual result was 583.36%, up 2043.0% from the prior year.
- FCF Margin retreated to 780.34% in Q1 2026 per NTLA's latest filing, from 301.16% in the prior quarter.
- Over five years, FCF Margin peaked at 4852.74% in Q4 2023 and troughed at 976.87% in Q3 2024.
- A 5-year average of 369.56% and a median of 696.07% in 2023 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin jumped 2256279 bps in 2022, then plunged 548172 bps in 2024.
- A 5-year view of FCF Margin shows it stood at 690.94% in 2022, then soared by 802 bps to 4852.74% in 2023, then plunged by 113 bps to 628.98% in 2024, then soared by 52 bps to 301.16% in 2025, then plunged by 159 bps to 780.34% in 2026.
- Business Quant data shows NTLA's FCF Margin at 780.34% in Q1 2026, 301.16% in Q4 2025, and 557.97% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -3.98% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 43.35% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Intellia Therapeutics | 1.86 Bn | 1.86 Bn | - | -780.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -780.34% |
| Dec 31, 2025 | -301.16% |
| Sep 30, 2025 | -557.97% |
| Jun 30, 2025 | -698.77% |
| Mar 31, 2025 | -896.20% |
| Dec 31, 2024 | -628.98% |
| Sep 30, 2024 | -976.87% |
| Jun 30, 2024 | -809.41% |
| Mar 31, 2024 | -425.67% |
| Dec 31, 2023 | 4,852.74% |
| Sep 30, 2023 | -790.53% |
| Jun 30, 2023 | -696.07% |
| Mar 31, 2023 | -897.67% |
| Dec 31, 2022 | -690.94% |
| Sep 30, 2022 | -623.87% |
| Jun 30, 2022 | -618.52% |
| Mar 31, 2022 | -742.29% |
| Dec 31, 2021 | -447.48% |
| Sep 30, 2021 | -23,186.67% |
| Jun 30, 2021 | -876.79% |